Navigation Links
Biomedical research center opens in Liverpool

Scientists at the University of Liverpool will launch a new national research centre to further understanding into infections such as HIV and tuberculosis.

The Centre, which will be opened by Sir William Stewart, Chairman of the Health Protection Agency, is one of 12 in the country to be funded by the National institute for Health Research (NIHR) as part of the Government's health research strategy. The joint venture has received 13.5 million funding from NIHR and a further 6.4million from the North West Development Agency. It will be run jointly by the University, the Royal Liverpool and Broadgreen University Hospitals Trust and the Liverpool School of Tropical Medicine.

The Centre will focus on four areas hospital and community acquired infections, chest infections, sexual health, and safety of antimicrobial drugs. Researchers will also have access to state-of-the-art facilities such as a new clinical research unit to trial new drug treatments and a medical microbiology facility for the identification and safe handling of bacteria.

Sir William said: "This is important work that will take place in first-rate facilities. I believe this Centre will be a magnet for our very best scientists, retaining and attracting the best brains to Liverpool and the North West, not just from elsewhere in the UK, but internationally. It is a privilege and pleasure to open such an important and worthwhile development."

Professor Peter Winstanley, Executive Director of the Biomedical Research Centre (BRC), said: "This prestigious new centre puts Liverpool at the cutting edge of research and means we can pioneer new drugs and diagnostic tools for a range of conditions. We will be investigating ways of alleviating suffering and treating infections which affect millions of people around the world."

The Centre will deliver 13 projects over the next five years, which include areas such as genetic testing to identify who is most likely to be allergic to penicillin, and vaccine development for pneumonia a major cause of death in children and adults worldwide. Research will also include identification of the factors that cause HIV patients to develop resistance to drug therapies.

Tony Bell, Royal Liverpool and Broadgreen University Hospitals Trust Chief Executive, said: "There has been groundbreaking medical research going on in Liverpool for many years.

The new Biomedical Research Centre acknowledges the excellence of that work and gives us the opportunity to make a much bigger impact on the treatment of infections worldwide. I am delighted to be part of such a vital development."

The opening of the Biomedical Research Centre will take place on Tuesday, 10 February at 11.00am in the Education Centre at the Royal Liverpool and Broadgreen University Hospital Trust.


Contact: Samantha Martin
University of Liverpool

Related medicine news :

1. Dr. Huda Zoghbi to receive 2009 Vilcek Prize in biomedical research
2. Environmental Tectonics Corporations BioMedical Division Announces Additional Sales of Hyperbaric Monoplace Chambers
3. USC awarded $22.2M NIH national biomedical informatics infrastructure coordinating center contract
4. BioMedical Enterprises, Inc. (BME) Announces the Appointment of Kenneth I. Moch as President and Chief Executive Officer
5. 5,000 Medical Leaders Report Latest Advancements in Biomedical Technologies; Breakthroughs by 2015 Predicted for Alzheimer's, Heart Disease, Cancer, and Diabetes
6. Response Biomedical Corporation Announces Change of Executives
7. Launches Doctor-Driven Biomedical Autism Treatment Website
8. ASH Holds a Special Symposium to Interest High School Students in Biomedical Research
9. ASH Honors Speaker of the House Nancy Pelosi and NHLBI Deputy Director Susan Shurin, MD, for Their Public Service, Leadership, and Commitment to Biomedical Research
10. Response Biomedical Corporation Announces Initiation of Respiratory Syncytial Virus Infection Clinical Trial
11. Environmental Tectonics Corporations BioMedical Systems Division Announces Additional Sales of its Baramed Monoplace Chambers
Post Your Comments:
(Date:10/12/2017)... ... , ... The American College of Medical Informatics (ACMI) will present the 2017 ... Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is ... pioneer in the field of medical informatics, this prestigious award is presented to an ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... system that we intend to develop to enable prevention of a major side ... severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA ...
(Date:10/12/2017)... Malvern, PA (PRWEB) , ... October 12, 2017 , ... ... is the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best ... New York City on October 11, 2017. , The annual award competition recognizes editorial ...
(Date:10/12/2017)... ... ... On Saturday, October 21, the Health & Wellness Center at Florida Hospital ... for the American Heart Association Heart Walk. Teams of up to 10 people can ... their treadmills moving for 5 hours. Treadmills will start at 7:00 p.m. on Saturday, ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... nation's first interactive health literacy software tool, and the Cancer Patient Education Network ... cancer patient education, today announce a new strategic alliance. , As CPEN’s ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... 27, 2017  Commended for their devotion to personalized service, ... as number one in the South Florida Business Journal,s 50 ... 5000 yearly list, the national specialty pharmacy has found its ... will soon be honored by SFBJ as the 2017 ... Set to receive his award in October, Bardisa said ...
(Date:9/25/2017)... AMSTERDAM , Sept. 25, 2017   ... Trial Master File solutions, today—from the IQPC Trial ... Amsterdam , NL)—announced that EastHORN Clinical Services ... its clinical programs and TMF management. EastHORN, a ... Montrium,s eTMF platform to increase transparency to enable ...
(Date:9/23/2017)... 2017 Janssen Biotech, Inc. (Janssen) announced today ... the U.S. Food and Drug Administration (FDA) for the ... the treatment of moderately to severely active rheumatoid arthritis ... are needed to further evaluate the safety of sirukumab ... "We are ...
Breaking Medicine Technology: